Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

4.260 -0.180 (-4.05%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 55,008,591
Open 4.510
Bid (Size) 4.380 (12,200)
Ask (Size) 4.390 (1,200)
Prev. Close 4.440
Today's Range 4.250 - 4.530
52wk Range 3.790 - 12.36
Shares Outstanding 168,425,907
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Myseum (NASDAQ: MYSE) Ignites “Picture Party,” a New Era in Social Media on All Apple (NASDAQ: AAPL) Devices Now! more stocks inside…
Via AB Newswire
Topics Artificial Intelligence
Why Recursion Pharmaceuticals Stock Vaulted 11% Higher on Wednesday ↗
Sentiment on the company has improved following solid clinical trial results from one of its pipeline drugs earlier this month. 
Via The Motley Fool
Topics Artificial Intelligence

Performance

YTD
-40.9%
-40.9%
1 Month
+5.7%
+5.7%
3 Month
-13.2%
-13.2%
6 Month
-15.3%
-15.3%
1 Year
-30.0%
-30.0%

More News

Read More
News headline image
Recursion Pharmaceuticals Stock Is Soaring Today: Here's Why ↗
Via Benzinga
News headline image
Oracle, Hut 8, Processa Pharmaceuticals, Recursion Pharmaceuticals, Udemy: Stocks Making The Biggest Moves Today ↗
Via Stocktwits
Topics Artificial Intelligence ETFs Stocks
News headline image
Earnings Scheduled For November 5, 2025 ↗
Via Benzinga
News headline image
Why Recursion Pharamaceuticals Topped the Market Today ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Jim Cramer: This Health Care Stock Has Been 'Horrendous' ↗
Via Benzinga
News headline image
10 AI Stocks Worth Buying Right Now ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Global Prescription Drug Market Poised for Trillion-Dollar Surge by 2035
Via MarketMinute
Topics Artificial Intelligence Death Intellectual Property
News headline image
Beyond the Hype: AI’s Quiet Revolution in Niche Sectors Reshapes Industries from Medicine to Agriculture
Via TokenRing AI
Topics Artificial Intelligence Economy Emissions
News headline image
Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
popEVE AI: Harvard-Developed Model Set to Revolutionize Rare Disease Diagnosis and Drug Discovery
Via TokenRing AI
Topics Artificial Intelligence
News headline image
Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence (AI) Stock? ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Is Recursion Pharmaceuticals a Meme Stock? ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033
From MarketNewsUpdates.com
Via GlobeNewswire
News headline image
Biopharma Boom: M&A Frenzy, AI Revolution, and GLP-1 Gold Rush Drive Robust Growth in 2025
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033
Via FinancialNewsMedia
News headline image
Forget Recursion Pharmaceuticals: This Could Be an Even Better Artificial Intelligence (AI) Stock ↗
Via The Motley Fool
Topics Animal Testing Artificial Intelligence
News headline image
AI Unlocks Gene-Editing Revolution: $2 Million Grant Propels Disease Cures
Via TokenRing AI
Topics Artificial Intelligence Climate Change Intellectual Property
News headline image
Nvidia's AI Reign: A $5 Trillion Bellwether Shaping Wall Street's Fortunes
Via MarketMinute
Topics Artificial Intelligence Economy Law Enforcement
News headline image
Recursion Pharmaceuticals (NASDAQ:RXRX) Reports Q3 2025 Results with Revenue Miss and Extended Cash Runway ↗
Via Chartmill
News headline image
Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion Announces CEO Transition Plan to Drive Next Phase of Growth
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
AI Unleashes a New Era in Cell and Gene Therapy: A Quarter Century Update Reveals Transformative Potential
Via TokenRing AI
Topics Artificial Intelligence

Frequently Asked Questions

Is Recursion Pharmaceuticals, Inc. - Class A Common Stock publicly traded?
Yes, Recursion Pharmaceuticals, Inc. - Class A Common Stock is publicly traded.
What exchange does Recursion Pharmaceuticals, Inc. - Class A Common Stock trade on?
Recursion Pharmaceuticals, Inc. - Class A Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Recursion Pharmaceuticals, Inc. - Class A Common Stock?
The ticker symbol for Recursion Pharmaceuticals, Inc. - Class A Common Stock is RXRX on the Nasdaq Stock Market
What is the current price of Recursion Pharmaceuticals, Inc. - Class A Common Stock?
The current price of Recursion Pharmaceuticals, Inc. - Class A Common Stock is 4.260
When was Recursion Pharmaceuticals, Inc. - Class A Common Stock last traded?
The last trade of Recursion Pharmaceuticals, Inc. - Class A Common Stock was at 12/19/25 04:00 PM ET
What is the market capitalization of Recursion Pharmaceuticals, Inc. - Class A Common Stock?
The market capitalization of Recursion Pharmaceuticals, Inc. - Class A Common Stock is 717.49M
How many shares of Recursion Pharmaceuticals, Inc. - Class A Common Stock are outstanding?
Recursion Pharmaceuticals, Inc. - Class A Common Stock has 717M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.